Avelumab (Bavencio): Mechanism and Clinical Trial Information
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
Avelumab (Bavencio) is a human anti-PD-L1 monoclonal antibody developed jointly by Merck KGaA and Pfizer. This immunotherapy is currently being evaluated in multiple clinical trials for various cancers, including gastric cancer and renal cell carcinoma (RCC).
Mechanism of Action
Avelumab works by binding to the PD-L1 (Programmed Death-Ligand 1) protein expressed on the surface of cancer cells. By blocking the interaction between PD-L1 and the PD-1 receptor on T-cells, Avelumab:
- Reactivates T-cells: Prevents cancer cells from "turning off" the immune system.
- Induces ADCC: Uniquely, Avelumab can trigger Antibody-Dependent Cellular Cytotoxicity (ADCC), leading to the direct destruction of cancer cells by natural killer (NK) cells.
Clinical Trial Spotlight: RCC (NCT02493751)
An early-phase clinical trial evaluated the combination of Avelumab and Inlyta (Axitinib) in patients with untreated advanced renal cell carcinoma.
Key Eligibility Criteria:
- Age 20 or older.
- Confirmed diagnosis of renal cell carcinoma.
- Prior nephrectomy (surgical removal of the primary tumor).
- ECOG Performance Status of 0 or 1.
- No prior systemic therapy for metastatic RCC.
Study Objectives:
The trial aimed to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) for the combination, while also assessing the safety and pharmacokinetics of the drugs.
Summary
As a potent anti-PD-L1 therapy, Avelumab represents a significant addition to the immunotherapy landscape. Its dual action of immune checkpoint inhibition and ADCC makes it a versatile candidate for combination therapies across multiple solid tumors.
Source: ClinicalTrials.gov - NCT02493751
#Avelumab #Bavencio #Immunotherapy #PDL1 #RenalCellCarcinoma #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4